Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Deucravacitinib Gastro-retentive Formulations in Healthy Participants
NCT06566768Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deucravacitinib in systemic lupus erythematosus (SLE) and Sjögren's syndrome (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 5 days, Concentration at 24 hours post dose and 1 more. Started Oct 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndrome
Beyond the preview
Go deeper on NCT06566768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566768.